Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $19.00 Price Target at Wells Fargo & Company

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price hoisted by Wells Fargo & Company from $18.00 to $19.00 in a report issued on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the biopharmaceutical company’s stock.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. lowered Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $80.00 to $36.00 in a report on Thursday, September 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Ultragenyx Pharmaceutical in a report on Tuesday, October 6th. HC Wainwright dropped their price objective on shares of Ultragenyx Pharmaceutical from $50.00 to $25.00 and set a “buy” rating for the company in a report on Thursday, September 3rd. Wedbush cut their price objective on shares of Ultragenyx Pharmaceutical from $25.00 to $22.00 and set a “neutral” rating for the company in a research report on Wednesday. Finally, Morgan Stanley lifted their target price on shares of Ultragenyx Pharmaceutical from $18.00 to $20.00 and gave the stock an “equal weight” rating in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $30.47.

Ultragenyx Pharmaceutical Stock Performance

Shares of Ultragenyx Pharmaceutical stock opened at $17.16 on Wednesday. Ultragenyx Pharmaceutical has a one year low of $12.73 and a one year high of $39.89. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -3.31 and a beta of 0.37. The business’s 50 day moving average price is $16.45 and its 200 day moving average price is $22.78.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.10) by ($0.06). The business had revenue of $173.00 million during the quarter, compared to the consensus estimate of $182.49 million. The business’s revenue was up 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.81) earnings per share. On average, analysts predict that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total transaction of $107,897.82. Following the completion of the sale, the chief financial officer owned 89,229 shares of the company’s stock, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 8,510 shares of company stock valued at $127,561 in the last ninety days. Corporate insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RARE. Parallel Advisors LLC grew its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,440 shares during the period. Sterling Capital Management LLC increased its position in shares of Ultragenyx Pharmaceutical by 102.4% during the 3rd quarter. Sterling Capital Management LLC now owns 2,475 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,252 shares during the last quarter. Leonteq Securities AG increased its position in shares of Ultragenyx Pharmaceutical by 288.5% during the 1st quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc increased its position in shares of Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares during the last quarter. Finally, EverSource Wealth Advisors LLC raised its holdings in Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,845 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Ultragenyx reaffirmed its 2026 revenue and 2027 profitability outlook. It also said expense reductions are expected to cut 2027 R&D spending by at least 50% versus 2025, and it has agreements to sell two priority review vouchers for a combined $413 million. The company also reported FDA approval of GENGLYCOS and FAYUVI in the third quarter. Company earnings release
• Neutral Sentiment: Analyst actions were mixed. TD Cowen raised its target to $19 and kept a Buy rating; Canaccord cut its target to $34 but retained Buy. Morgan Stanley raised its target to $22 with an Equal Weight rating, while Goldman Sachs and Wedbush lowered targets to $17 and $22, respectively, and kept neutral ratings. Analyst ratings
• Negative Sentiment: Third-quarter revenue was $173 million, up 8.2% year over year but below the $182.49 million consensus. The $1.16-per-share loss also missed estimates of $1.10. A Seeking Alpha analysis additionally flagged reliance on CRYSVITA, limited contributions from newer launches, and pipeline setbacks; it argued the profitability pivot depends heavily on deep R&D cuts. Seeking Alpha analysis

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.